---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001274"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T00:32:14.414435+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Agenus Q2 2023 net loss $73.4M; bot/bal combo mOS 20.9 months in CRC, FDA Fast Track

## Summary
- Q2 revenue $25.3M, net loss $73.4M ($0.20 EPS); cash $157.6M at June 30, down from $193.4M at Dec 2022.
- Bot/bal combo in 3L+ Non-MSI-H CRC: mOS 20.9 months vs 12.9 SOC; ORR 23% vs 2.8%; FDA Fast Track granted.
- ACTIVATE Phase 2 CRC and melanoma trials on target to fully enroll by end of 2023; BLA submission planned in 2024.
- AGEN2373 monotherapy shows clinical responses in prostate, ampullary, vulvar cancers; first CD137 agonist with no hepatic toxicity.
- Leadership appointments: Robin Taylor (CCO), Homa Yeganegi (Chief Product Strategy & Global Medical Affairs), Stephanie Fagan (CCO).

## SEC filing metadata
- accession: 0001157523-23-001274
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000115752323001274/0001157523-23-001274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000115752323001274/a53512783.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001274
- JSON: https://secwatch.observer/filing/0001157523-23-001274.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001274.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.